EyeCRO scientists contribute to paper published in Biology
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization
Similar Posts
Activation of the molecular chaperone, sigma 1 receptor, preserves cone function in a murine model of inherited retinal degeneration.
Retinal degenerative diseases are major causes of untreatable blindness, and novel approaches to treatment are being sought actively. Here we explored the activation of a unique protein, sigma 1 receptor (Sig1R), in the treatment of PRC loss because of its multifaceted role in cellular survival. We used Pde6βrd10 (rd10) mice, which harbor a mutation in…
Nanotechnology Paves the Way for Advances in Genome Sequencing
The first human genome sequencing was accomplished after 13 painstaking years of research at the cost of $3 billion. But recent advances in sequencing technology holds promise of rapid increase in speed of sequencing at the rate of 6 billion nucleotide bases every 6 h at a cost below $1000. http://www.azonano.com/news.aspx?newsID=24912
Roche CEO ‘sleeps better’ as risk to drugmaker’s growth recedes
LONDON (Reuters) – Roche (ROG.S) is increasingly confident it will continue to lift sales and profit even as cut-rate copies of the Swiss drugmaker’s older cancer medicines start to grab business next year, its chief executive said on Wednesday. In February the company won U.S. Food and Drug Administration (FDA) breakthrough status for new multiple…
Patient-reported outcomes and visual acuity after 12 months of anti-VEGF-treatment for sight-threatening diabetic macular edema in a real world setting
This study was an evaluation, at 12 months follow-up, of anti VEGF treatment for diabetic macular edema conducted in a real world setting. To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated…
Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger
Avalanche Biotechnologies, Inc. (“Avalanche”) (AAVL) and Annapurna Therapeutics SAS (“Annapurna”), a privately held biopharmaceutical company, today announced that they have entered into a definitive agreement providing for the acquisition of all outstanding shares of Annapurna by Avalanche in exchange for approximately 17.6 million newly issued shares of Avalanche common stock. Upon completion of the proposed…
Calcium carbonate templates for drug delivery
The fast and targeted delivery of drugs to the focus of a disease could soon be made easier. Helmuth Möhwald and his colleagues from the Max Planck Institute of Colloids and Interfaces in Golm, Potsdam, have developed a simple technique for the production of drug containers which can be channelled to a selected target in…
